SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
Year: 2024
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Annals of Oncology
Authors: A.C. Garrido-Castro, S.E. Kim, T. Li, J. Desrosiers, R. Nanda, Y. Abdou, A.S. Clark, R.L. Sacks, T. O’Connor, N. Sinclair, S. Lo, G. Augdahl, E. Wrabel, M. DiLullo, T. Rahman, A. Patel, M.E. Hughes, J. Baginska, P.B. Lange, T. O’Meara, T.E. Keenan, A. Gorthi, A. D’Ippolito, C.A. Painter, M. Eaton, J.C. Barrett, B. Koca, P.T. Kurnia, A.N. Perry, J. Gomez Tejeda Zanudo, M. He, D.A. Dillon, N.U. Lin, H.J. Burstein, E.A. Mittendorf, R. Jeselsohn, D.L. Rimm, N. Tayob, S.M. Tolaney
Institutions: Harvard University, Dana-Farber Cancer Institute, University of Chicago, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, University of Pennsylvania, Emory University Hospital, Winship Cancer Institute, Dana-Farber Brigham Cancer Center, Stamford Hospital, Yale University, Brigham and Women's Hospital, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399374789